ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 110 filers reported holding ERASCA INC in Q3 2023. The put-call ratio across all filers is 1.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $40,102 | -28.2% | 20,356 | +0.5% | 0.00% | – |
Q2 2023 | $55,887 | +2.8% | 20,249 | +12.1% | 0.00% | – |
Q1 2023 | $54,349 | -31.7% | 18,056 | -2.2% | 0.00% | – |
Q4 2022 | $79,588 | -41.0% | 18,466 | +6.0% | 0.00% | -100.0% |
Q3 2022 | $135,000 | +45.2% | 17,425 | +3.9% | 0.00% | – |
Q2 2022 | $93,000 | -55.9% | 16,775 | -31.6% | 0.00% | – |
Q1 2022 | $211,000 | -37.6% | 24,533 | +13.2% | 0.00% | -100.0% |
Q4 2021 | $338,000 | – | 21,675 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 11,055,554 | $21,779,441 | 14.15% |
EDBI Pte Ltd | 888,888 | $1,751,109 | 1.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 1,926,000 | $3,794,220 | 1.28% |
Cormorant Asset Management, LP | 10,813,246 | $21,302,095 | 1.24% |
AH Equity Partners LSV II, L.L.C. | 312,500 | $615,625 | 0.64% |
Artal Group S.A. | 4,721,194 | $9,301 | 0.40% |
PFM Health Sciences, LP | 3,930,633 | $7,743,347 | 0.36% |
ARMISTICE CAPITAL, LLC | 8,356,000 | $16,461,320 | 0.25% |
SANDERS MORRIS HARRIS LLC | 425,297 | $816,569 | 0.17% |
Prosight Management, LP | 264,710 | $521,479 | 0.16% |